Cadila Healthcare Receives USFDA Green Signal For Doxazosin Tablets

Cadila Healthcare announced that it has received the final approval from the USFDA to market Doxazosin tablets USP 1mg, 2mg, 4mg and 8mg. The drug is a selective alpha blocker used to treat high blood pressure and urinary retention associated with benign prostatic hyperplasia.

The company had received the tentative approval from the USFDA to market Lurasidone Hydrochloride tablets 20 mg, 40 mg, 60 mg and 120 mg. The drug is an atypical anti-psychotic used in the treatment of schizophrenia.

Both Doxazosin tablets and Lurasidone Hydrochloride tablets will be produced the company's formulation manufacturing facility at the Pharma SEZ in Ahmedabad.

The pharma major has more than 120 approvals and has so far filled over 300 ANDAs since the commencement of the filing process in FY 2003-04.

For Quick Trial – 8962000225 ✔
or mail us here:
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717 
Share on Google Plus Share on Pinterest

About Suhani Varma

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.